分子质量控制有助于监控测试程序的性能。这些测试有助于获得关键且准确的诊断信息。这些对照也用于确定传染性疾病和遗传性疾病。此外,分子质量控制还有助于监测医疗保健相关感染、病毒载量测定和性传播感染的核酸检测方案的性能。
亚太分子质量控制市场预计将达到7207万美元从 2021 年的 3,427 万美元增至 2028 年;预计 2021 年至 2028 年复合年增长率为 11.2%。个性化药物需求的增长、测序成本的下降以及遗传疾病患病率的增加等因素推动了市场的增长。然而,熟练专业人员的缺乏阻碍了市场的增长。
根据世界卫生组织的建议,30-50%的癌症死亡可以通过早期充分治疗来预防。阶段。在这种情况下,个性化医疗提供了最有前途的方法来解决那些尚未众所周知对现有治疗或治愈方法做出有效反应的疾病。此外,数字化使医生能够根据肿瘤或癌组织的基因组成来决定患者的癌症治疗。因此,这些进步使个性化医疗成为现实,通过开发高度针对性的疗法,提供改善治疗结果的潜力,特别是对于癌症患者。此外,个性化医疗考虑遗传、环境和生活方式的变异性。因此,基于患者遗传信息的个性化药物越来越多地用于疾病治疗,预计将成为未来几年分子质量控制市场的显着趋势。此外,基因组测序以及下一代测序的成本在过去 6 至 7 年中大幅下降。此外,该过程需要更少的天数才能完成。降低成本和加速整体流程使服务提供商能够获得更大的利润率,同时帮助他们扩大客户群。因此,基因组测序成本的降低推动了为不同目的而进行的分子生物学程序的数量,从而推动了分子质量控制的使用。
亚太地区受 COVID-19 大流行爆发的严重影响。 COVID-19 流行率的上升以及用于检测 COVID-19 的 PCR 检测的推出支持了市场在不久的将来的预测期内的增长。该地区日益增强的质量保证举措也可能有利于市场增长。例如,在印度,印度医学研究委员会分配了 30 个质量控制 (QC) 实验室来验证各自领域其他实验室的结果。这有助于建立诊断质量。因此,COVID-19大流行的爆发预计将对亚太地区分子质量控制行业产生重大影响。
亚太地区分子质量控制市场按产品划分为独立控制和仪器专用控制。独立控制细分市场在 2020 年占据了更大的市场份额,而预计在预测期内该细分市场的复合年增长率最高。
根据分析物类型,亚太地区分子质量控制市场已分为单一分析物控制和多分析物控制。单一分析物对照品细分市场在 2020 年占据了更大的市场份额,而多分析物对照品细分市场预计在预测期内的复合年增长率最高。
亚太地区分子质量控制市场按应用细分为传染病、肿瘤学、基因检测和其他应用。 2020 年,传染病细分市场占据最大市场份额,而肿瘤细分市场预计在预测期内的复合年增长率最高。
基于最终结果用户方面,亚太分子质量控制市场分为临床实验室、医院、IVD 制造商和医疗机构。合同研究组织、学术和研究机构研究机构和其他最终用户。临床实验室细分市场在 2020 年占据最大市场份额,预计在预测期内复合年增长率最高。
< /p>
一些主要和次要来源与这份亚太分子质量控制市场报告相关的机构包括北京基因组研究所 (BGI)、生物技术产业研究援助委员会 (BIRAC)、国家生物技术信息中心 (NCBI) 和癌症基因组学与先进治疗中心 (C-CAT) ).
  ;
Strategic insights for Asia Pacific Molecular Quality Controls involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 34.27 Million |
Market Size by 2028 | US$ 72.07 Million |
Global CAGR (2021 - 2028) | 11.2% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By 产品
|
Regions and Countries Covered | 亚太地区
|
Market leaders and key company profiles |
The regional scope of Asia Pacific Molecular Quality Controls refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Molecular Quality Controls Market is valued at US$ 34.27 Million in 2021, it is projected to reach US$ 72.07 Million by 2028.
As per our report Asia Pacific Molecular Quality Controls Market, the market size is valued at US$ 34.27 Million in 2021, projecting it to reach US$ 72.07 Million by 2028. This translates to a CAGR of approximately 11.2% during the forecast period.
The Asia Pacific Molecular Quality Controls Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Molecular Quality Controls Market report:
The Asia Pacific Molecular Quality Controls Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Molecular Quality Controls Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Molecular Quality Controls Market value chain can benefit from the information contained in a comprehensive market report.